HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Christophe Lurquin Selected Research

GCS-100

10/2010A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Christophe Lurquin Research Topics

Disease

10Neoplasms (Cancer)
11/2017 - 01/2002
6Melanoma (Melanoma, Malignant)
02/2011 - 10/2002
3Neoplasm Metastasis (Metastasis)
02/2011 - 01/2005

Drug/Important Bio-Agent (IBA)

7AntigensIBA
02/2011 - 01/2002
4Neoplasm Antigens (Tumor Antigens)IBA
02/2011 - 01/2005
3VaccinesIBA
02/2011 - 01/2005
2Peptides (Polypeptides)IBA
02/2011 - 11/2003
2HLA-A1 Antigen (HLA A1 Antigen)IBA
01/2005 - 11/2003
1Fas Ligand Protein (Fas Ligand)IBA
11/2017
1Cancer VaccinesIBA
11/2017
1Immune Checkpoint InhibitorsIBA
11/2017
1Melanoma-Specific AntigensIBA
02/2011
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
02/2011
1HLA-A2 Antigen (HLA A2 Antigen)IBA
02/2011
1LigandsIBA
10/2010
1Galectin 3 (LGALS3)IBA
10/2010
1GCS-100IBA
10/2010

Therapy/Procedure

4Immunotherapy
11/2017 - 01/2002
1Therapeutics
11/2017
1Injections
10/2010